as 12-18-2024 4:00pm EST
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
Founded: | 1980 | Country: | United States |
Employees: | N/A | City: | BASKING RIDGE |
Market Cap: | 24.2M | IPO Year: | N/A |
Target Price: | $15.00 | AVG Volume (30 days): | 19.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.51 | EPS Growth: | N/A |
52 Week Low/High: | $2.19 - $3.83 | Next Earning Date: | 11-12-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
LSTA Breaking Stock News: Dive into LSTA Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
7 days ago
Exec Edge
7 days ago
GlobeNewswire
8 days ago
Medical Device Network
15 days ago
MT Newswires
15 days ago
GlobeNewswire
15 days ago
GlobeNewswire
a month ago
Thomson Reuters StreetEvents
a month ago
The information presented on this page, "LSTA Lisata Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.